Amgen and TScan Therapeutics, Inc. entered a multi-year collaboration that will use TScan’s TargetScan discovery platform to identify the antigens recognized by T cells in patients with Crohn’s disease. TScan will receive a $30 million upfront and is eligible to earn over $500 million in success-based preclinical, clinical, regulatory and commercial milestones as well as royalty payments.    Amgen will evaluate a variety of modalities to create therapeutics based on targets discove...